- Home
- OVID vs DYAI Comparison
OVID vs DYAI Comparison
Compare OVID & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVID
- DYAI
- Stock Information
- Founded
- OVID 2014
- DYAI 1979
- Country
- OVID United States
- DYAI United States
- Employees
- OVID N/A
- DYAI N/A
- Industry
- OVID Biotechnology: Pharmaceutical Preparations
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OVID Health Care
- DYAI Health Care
- Exchange
- OVID Nasdaq
- DYAI Nasdaq
- Market Cap
- OVID 47.1M
- DYAI 54.4M
- IPO Year
- OVID 2017
- DYAI 2004
- Fundamental
- Price
- OVID $0.31
- DYAI $1.35
- Analyst Decision
- OVID Strong Buy
- DYAI Strong Buy
- Analyst Count
- OVID 6
- DYAI 1
- Target Price
- OVID $3.03
- DYAI $6.00
- AVG Volume (30 Days)
- OVID 343.6K
- DYAI 60.6K
- Earning Date
- OVID 03-11-2025
- DYAI 03-26-2025
- Dividend Yield
- OVID N/A
- DYAI N/A
- EPS Growth
- OVID N/A
- DYAI N/A
- EPS
- OVID N/A
- DYAI N/A
- Revenue
- OVID $566,000.00
- DYAI $3,495,389.00
- Revenue This Year
- OVID N/A
- DYAI $51.30
- Revenue Next Year
- OVID $36.11
- DYAI $73.26
- P/E Ratio
- OVID N/A
- DYAI N/A
- Revenue Growth
- OVID 44.39
- DYAI 20.58
- 52 Week Low
- OVID $0.31
- DYAI $0.93
- 52 Week High
- OVID $3.45
- DYAI $2.67
- Technical
- Relative Strength Index (RSI)
- OVID 22.55
- DYAI 42.96
- Support Level
- OVID $0.42
- DYAI $1.29
- Resistance Level
- OVID $0.48
- DYAI $1.45
- Average True Range (ATR)
- OVID 0.05
- DYAI 0.10
- MACD
- OVID -0.01
- DYAI -0.00
- Stochastic Oscillator
- OVID 1.73
- DYAI 31.03
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
About DYAI Dyadic International Inc.
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.